Synergy of arbekacin-based combinations against vancomycin hetero-intermediate Staphylococcus aureus

Journal of Korean Medical Science

Volumn 21, Issue 2, 2006, Pages 188-192

  Lee, Ji Young ^a   Won, Sup Oh ^a   Kwan, Soo Ko ^a   Sang, Taek Heo ^a   Chi, Sook Moon ^a   Hyun, Kyun Ki ^a   Kiem, Sungmin ^a   Kyong, Ran Peck ^a   Song, Jae Hoon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Arbekacin; Habekacin; hetero VISA; Rifampin; Staphylococcus aureus; Sultamicillin; Teicoplanin quinipristin dalfopristin; Time kill assay; Vancomycin Resistance

Indexed keywords

EID: 33646784384     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2006.21.2.188     Document Type: Article

References (31)

1. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6.
2. Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 2002; 56: 657-75.
3. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GR, Brown WJ, Cardo D, Fridkin SK; Vancomycin-Resistant Staphylococcus aureus Investigative Team. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348: 1342-7.
4. Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, Flannagan SE, Kolonay JF, Shetty J, Killgore GE, Tenover FC. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 2003; 302: 1569-701.
5. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus - New York, 2004. Morb Mortal Wkly Rep 2004; 53: 322-3.
6. Ariza J, Pujol M, Cabo J, Pena C, Fernandez N, Linares J, Ayats J, Gudiol F. Vancomycin in surgical infections due to methicillin-resistance Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999; 353: 1587-8.
7. Howe RA, Bowker KE, Walsh TR, Feest TG, MacGowan AP. Vancomycin resistance Staphylococcus aureus. Lancet 1998; 351: 602.
8. Kim MN, Pai CH, Woo JH, Ryu JS, Hiramatsu K. Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol 2000; 38: 3879-81.
9. Ploy MC, Grelaud C, Martin C, de Lumely L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351: 1212.
10. Wong SS, Ho PL, Woo PC, Yuen KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 1999; 29: 760-7.
11. Bert F, Clarissou J, Durand F, Delefosse D, Chauvet C, Lefebvre P, Lambert N, Branger C. Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in live transplant recipients. J Clin Microbiol 2003; 41: 5147-52.
12. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003; 47: 1262-6.
13. Naimi TS, Anderson D, O'Boyle C, Boxrud DJ, Johnson SK, Tenover FC, Lynfield R. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. Clin Infect Dis 2003; 36: 1609-12.
14. Watanabe T, Ohashi K, Matsui K, Kubota T. Comparative studies of the bactericical, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1997; 39: 471-6.
15. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001; 1: 147-55.
16. Kondo S, Iinuma K, Yamamoto H, Maeda K, Umezawa H. Synthesis of 1-N-(S-4-amino-2-hydroxybutyryl)-kanamycin B and 3′-, 4′- dideoxykanamycin B active against kanamycin-resistant bacteria. J Antibiotics 1973; 26: 412-5.
17. Kondo S, Tamura A, Gomi S, Ikeda Y, Takeuchi T, Mitsuhashi S. Structures of enzymatically modified products of arbekacin by meticillin-resistant Staphylococcus aureus. J Antibiotics 1993; 46: 310-5.
18. Osakabe Y, Takahashi Y, Narihara K. The utility and dosage and administration of arbekacin in patients with MRSA infection. Antibiotics Chemother 1996; 12: 120-7.
19. Hamilton-Miller MT, Shah S. Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococus aureus. J Antimicrob Chemother 1995; 35: 865-68.
20. You I, Kariyama R, Zervos MJ, Kumon H, Chow JW. In-vitro activity of arbekacin alone and in combination with vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2000; 36: 37-41.
21. NCCLS. Performance standards for antimicrobial susceptibility testing; 13th Informational Supplement. 2003; M100-S13.
22. Eliopoulos GM, Moellering RC. Antimicrobial combinations. In: Antibiotics in Laboratory Medicine. Lorian V, editor, 4th edn, Baltimore: Williams & Wilkins, 1996; 330-96.
23. LaPante KL, Rybak MJ. Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diag Microbiol Infect Dis 2004; 50: 125-30.
24. Wong SS, Ho PL, Woo PC, Yuen KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 1999; 29: 760-7.
25. Tenover FC, Weigel LM, Appelbaum PC, McDougal LK, Chaitram J, McAllister S, Clark N, Killgore G, O'Hara CM, Jevitt L, Patel JB, Bozdogan B. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004; 48: 275-80.
26. Whitener CJ, Park SY, Browne FA, Parent LJ, Julian K, Bozdogan B, Appelbaum PC, Chaitram J, Weigel LM, Jernigan J, McDougal LK, Tenover FC, Fridkin SK. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis 2004; 38: 1049-55.
27. Hotta K, Zhu CB, Ogata T, Sunada A, Ishikawa J, Mizuno S, Ikeda Y, Kondo S. Enzymatic 2″-N-acetylation of arbekacin and antibiotic activity of its product. J Antibiotics 1996; 49: 458-64.
28. Suzuki K. Efficacy and safety of arbekacin for staphylococcal infection in the NICU. Pediatr Int 2003; 45: 301-6.
29. Akins PL, Rybak MJ. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother 2000; 44: 1925-9.
30. Lee DG, Chun HS, Yim DS, Choi SM, Choi JH, Yoo JH, Shin WS, Kang MW. Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model. Antimicrob Agents Chemother 2003; 47: 3768-73.
31. Kumon H, Mizuno A, Nasu Y, Tsugawa M, Kishi M, Ohmori H. Pharmacokinetics of arbekacin in healthy volunteers and patients with renal insufficiency. Jpn J Antibiotics 1989; 42: 200-7.